Company Report

Company Reports / Novartis

COMPANY: Novartis

INDEX RANK: 2nd

Total Impact Score: 12,918,868.71

Novartis is ranked 2nd place in our index for 2015. Novartis’s drugs have a total impact score of 12,918,868.71. Novartis treats two diseases in our model - P. falc malaria and P. vivax malaria - with one drug - Artemether-Lumefantrine (AL). Novartis receives credit for one treatment against P. falc malaria - Artemether-Lumefantrine (AL). This one drug averted 12,918,639.54 of the total DALYS for P. falc malaria, which is 56.81% of the worldwide DALYs that we estimate would have been lost due to P. falc malaria in 2015 in the absence of effective treatment. Novartis’s drug portfolio placed it 1st in terms of total averted DALYs for P. falc malaria. Novartis receives credit for one treatment against P. vivax malaria - Artemether-Lumefantrine (AL). This one drug averted 194.46 of the total DALYS for P. vivax malaria, which is 0.05% of the worldwide DALYs that we estimate would have been lost due to P. vivax malaria in 2015 in the absence of effective treatment. Novartis’s drug portfolio placed it 4th in terms of total averted DALYs for P. vivax malaria.

Company Score Breakdown:

Key Drugs

ARTEMETHER+LUMEFANTRINE (AL)

Artemether+Lumefantrine (AL) is an artemisinin-based combination therapy recommended by the WHO as one of the primary treatments for both uncomplicated and severe malaria. It is generally as safe and effective as AS+MQ, but is more likely to cause earlier relapses because lumefantrine is eliminated more rapidly than some other ACTs such as mefloquine. AL was patented by Novartis in 2009.

Company Information

Novartis is a global pharmaceutical company headquartered in Basel, Switzerland and established in 1996 by the merger of Ciba-Geigy and Sandoz Laboratories. The company focuses on a range of disease areas including: oncology, respiratory, cardio-metabolic, neuroscience, and immunology/dermatology. Major products include Gilenya®, Cosentyx® and Gleevec®. Novartis works to expand access to medicines for malaria through several initiatives including a zero-profit model to malariaendemic countries that reached 43.7 million people in 2017, clinical trials researching two novel antimalarial drug candidates, and a renewed, 5-year, $100 million R&D investment to help reach the WHO’s 2030 malaria elimination targets. Novartis also expands access to medicine by not enforcing patents in LICs and LDCs and through the Novartis Access Program which treats public-sector customers with chronic illnesses for one USD per treatment, per month. In 2017 they had 126,000 employees in 155 countries and a revenue of $49.1 billion.

Company Report PDF